| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis, Knee | 109 | 2025 | 271 | 16.430 |
Why?
|
| Knee Joint | 53 | 2025 | 171 | 6.900 |
Why?
|
| Osteoarthritis | 16 | 2023 | 104 | 4.240 |
Why?
|
| Arthroplasty, Replacement, Knee | 22 | 2023 | 151 | 4.140 |
Why?
|
| Osteoarthritis, Hip | 21 | 2023 | 61 | 3.600 |
Why?
|
| Cartilage, Articular | 26 | 2023 | 64 | 3.170 |
Why?
|
| Chronic Pain | 8 | 2025 | 149 | 2.410 |
Why?
|
| Synovitis | 10 | 2022 | 26 | 2.190 |
Why?
|
| Magnetic Resonance Imaging | 48 | 2025 | 3845 | 2.000 |
Why?
|
| Arthralgia | 11 | 2024 | 68 | 1.580 |
Why?
|
| Disease Progression | 35 | 2024 | 2240 | 1.430 |
Why?
|
| Patient Preference | 4 | 2017 | 135 | 1.370 |
Why?
|
| Pain | 21 | 2024 | 481 | 1.360 |
Why?
|
| Pain Management | 8 | 2025 | 199 | 1.310 |
Why?
|
| Aged | 96 | 2025 | 21687 | 1.240 |
Why?
|
| Middle Aged | 103 | 2025 | 29314 | 1.170 |
Why?
|
| Rheumatic Diseases | 3 | 2019 | 72 | 1.130 |
Why?
|
| Joints | 4 | 2016 | 26 | 1.120 |
Why?
|
| Carpal Tunnel Syndrome | 2 | 2024 | 23 | 1.020 |
Why?
|
| Pain Measurement | 20 | 2025 | 368 | 1.000 |
Why?
|
| Exercise | 10 | 2023 | 869 | 0.900 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 474 | 0.880 |
Why?
|
| Humans | 148 | 2025 | 133748 | 0.870 |
Why?
|
| Osteoporosis | 2 | 2022 | 140 | 0.830 |
Why?
|
| Male | 107 | 2025 | 65884 | 0.820 |
Why?
|
| Radiography | 19 | 2025 | 825 | 0.820 |
Why?
|
| Exercise Therapy | 5 | 2020 | 182 | 0.790 |
Why?
|
| Female | 100 | 2025 | 71644 | 0.740 |
Why?
|
| Hand Joints | 3 | 2020 | 6 | 0.740 |
Why?
|
| Diphosphonates | 1 | 2021 | 43 | 0.720 |
Why?
|
| Antirheumatic Agents | 3 | 2019 | 124 | 0.700 |
Why?
|
| Bone Density Conservation Agents | 1 | 2021 | 56 | 0.700 |
Why?
|
| Rheumatology | 4 | 2023 | 129 | 0.700 |
Why?
|
| Patient Satisfaction | 4 | 2012 | 484 | 0.700 |
Why?
|
| Arthritis | 2 | 2019 | 86 | 0.690 |
Why?
|
| Longitudinal Studies | 18 | 2024 | 1497 | 0.680 |
Why?
|
| Health Status Disparities | 2 | 2021 | 249 | 0.680 |
Why?
|
| Walking | 7 | 2023 | 234 | 0.660 |
Why?
|
| Socioeconomic Factors | 8 | 2019 | 920 | 0.650 |
Why?
|
| Menisci, Tibial | 9 | 2021 | 38 | 0.650 |
Why?
|
| Risk Assessment | 7 | 2021 | 3708 | 0.640 |
Why?
|
| Platelet-Rich Plasma | 1 | 2019 | 18 | 0.630 |
Why?
|
| Opportunistic Infections | 1 | 2019 | 80 | 0.620 |
Why?
|
| Severity of Illness Index | 20 | 2022 | 3098 | 0.600 |
Why?
|
| Interleukins | 1 | 2019 | 130 | 0.600 |
Why?
|
| Bone Marrow | 5 | 2016 | 335 | 0.600 |
Why?
|
| Wrist Joint | 2 | 2022 | 28 | 0.600 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2019 | 87 | 0.600 |
Why?
|
| Cross-Sectional Studies | 24 | 2024 | 3743 | 0.590 |
Why?
|
| Analgesics, Opioid | 6 | 2022 | 460 | 0.580 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 180 | 0.580 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 316 | 0.550 |
Why?
|
| Glucosamine | 2 | 2014 | 12 | 0.540 |
Why?
|
| Osteophyte | 4 | 2022 | 7 | 0.520 |
Why?
|
| Diagnostic Imaging | 2 | 2021 | 317 | 0.510 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2024 | 294 | 0.510 |
Why?
|
| Drug Overdose | 3 | 2022 | 75 | 0.490 |
Why?
|
| Health Services Accessibility | 4 | 2017 | 648 | 0.480 |
Why?
|
| United States | 32 | 2023 | 11714 | 0.480 |
Why?
|
| Bone Marrow Diseases | 2 | 2012 | 41 | 0.480 |
Why?
|
| Psychotherapy | 2 | 2017 | 246 | 0.470 |
Why?
|
| Surgeons | 3 | 2023 | 284 | 0.460 |
Why?
|
| Arthroplasty, Replacement, Hip | 5 | 2011 | 111 | 0.450 |
Why?
|
| Veterans | 8 | 2022 | 1779 | 0.440 |
Why?
|
| Logistic Models | 13 | 2019 | 1908 | 0.430 |
Why?
|
| Overweight | 2 | 2022 | 386 | 0.430 |
Why?
|
| Tibia | 6 | 2022 | 83 | 0.430 |
Why?
|
| Cohort Studies | 18 | 2024 | 5194 | 0.430 |
Why?
|
| Disability Evaluation | 4 | 2020 | 195 | 0.420 |
Why?
|
| Quality of Life | 4 | 2016 | 2149 | 0.410 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1069 | 0.410 |
Why?
|
| Motor Activity | 6 | 2015 | 539 | 0.410 |
Why?
|
| Cartilage Diseases | 3 | 2022 | 15 | 0.410 |
Why?
|
| Risk Factors | 23 | 2023 | 11122 | 0.390 |
Why?
|
| Prospective Studies | 24 | 2023 | 6592 | 0.390 |
Why?
|
| Leisure Activities | 1 | 2012 | 10 | 0.390 |
Why?
|
| Arthritis, Juvenile | 1 | 2012 | 42 | 0.380 |
Why?
|
| Time Factors | 15 | 2021 | 6583 | 0.380 |
Why?
|
| Internet | 2 | 2014 | 403 | 0.370 |
Why?
|
| Sleep Wake Disorders | 3 | 2020 | 187 | 0.350 |
Why?
|
| Femur | 6 | 2022 | 75 | 0.350 |
Why?
|
| Treatment Outcome | 14 | 2025 | 13007 | 0.340 |
Why?
|
| Aged, 80 and over | 20 | 2022 | 7198 | 0.340 |
Why?
|
| Recovery of Function | 5 | 2020 | 465 | 0.340 |
Why?
|
| Tibial Meniscus Injuries | 3 | 2016 | 31 | 0.320 |
Why?
|
| Healthcare Disparities | 4 | 2019 | 478 | 0.300 |
Why?
|
| Muscle Strength | 3 | 2013 | 86 | 0.290 |
Why?
|
| Acupuncture Therapy | 1 | 2007 | 13 | 0.280 |
Why?
|
| Physician-Patient Relations | 2 | 2011 | 448 | 0.280 |
Why?
|
| Cartilage | 4 | 2022 | 51 | 0.280 |
Why?
|
| Electronic Mail | 1 | 2007 | 43 | 0.270 |
Why?
|
| Sex Factors | 4 | 2020 | 1386 | 0.270 |
Why?
|
| Joint Prosthesis | 3 | 2008 | 18 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 1213 | 0.270 |
Why?
|
| Prejudice | 2 | 2021 | 39 | 0.270 |
Why?
|
| Gait | 3 | 2017 | 148 | 0.260 |
Why?
|
| Activities of Daily Living | 5 | 2018 | 432 | 0.260 |
Why?
|
| Electric Stimulation Therapy | 1 | 2007 | 109 | 0.260 |
Why?
|
| Scleroderma, Diffuse | 2 | 2016 | 4 | 0.240 |
Why?
|
| Odds Ratio | 6 | 2023 | 1338 | 0.240 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2025 | 21 | 0.230 |
Why?
|
| Self Efficacy | 2 | 2020 | 207 | 0.230 |
Why?
|
| Ligaments, Articular | 1 | 2024 | 22 | 0.220 |
Why?
|
| Catastrophization | 2 | 2025 | 18 | 0.220 |
Why?
|
| Perception | 2 | 2011 | 236 | 0.220 |
Why?
|
| Predictive Value of Tests | 10 | 2021 | 2297 | 0.220 |
Why?
|
| Adult | 22 | 2024 | 31892 | 0.220 |
Why?
|
| Neoplasms | 1 | 2019 | 3029 | 0.220 |
Why?
|
| Linear Models | 6 | 2018 | 722 | 0.220 |
Why?
|
| Patient Selection | 3 | 2025 | 734 | 0.220 |
Why?
|
| Pressure | 1 | 2024 | 136 | 0.220 |
Why?
|
| Cachexia | 1 | 2024 | 57 | 0.220 |
Why?
|
| Case-Control Studies | 12 | 2022 | 3654 | 0.220 |
Why?
|
| Cadaver | 1 | 2024 | 138 | 0.220 |
Why?
|
| Bicycling | 1 | 2024 | 36 | 0.220 |
Why?
|
| Incidence | 8 | 2022 | 3408 | 0.220 |
Why?
|
| Actigraphy | 3 | 2019 | 47 | 0.220 |
Why?
|
| Synovial Membrane | 2 | 2014 | 27 | 0.220 |
Why?
|
| Focus Groups | 1 | 2004 | 211 | 0.210 |
Why?
|
| Isometric Contraction | 2 | 2013 | 26 | 0.210 |
Why?
|
| Hip Prosthesis | 2 | 2005 | 10 | 0.210 |
Why?
|
| Obesity | 4 | 2022 | 2433 | 0.210 |
Why?
|
| Resistance Training | 1 | 2023 | 30 | 0.210 |
Why?
|
| Self Report | 4 | 2019 | 553 | 0.210 |
Why?
|
| Biomechanical Phenomena | 7 | 2021 | 260 | 0.210 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 206 | 0.200 |
Why?
|
| Crystal Arthropathies | 1 | 2022 | 5 | 0.200 |
Why?
|
| Prevalence | 7 | 2020 | 2668 | 0.200 |
Why?
|
| Hypesthesia | 1 | 2022 | 11 | 0.200 |
Why?
|
| Wrist | 1 | 2022 | 27 | 0.200 |
Why?
|
| Analgesics | 2 | 2021 | 134 | 0.200 |
Why?
|
| Quadriceps Muscle | 2 | 2013 | 17 | 0.200 |
Why?
|
| Knee | 3 | 2014 | 21 | 0.200 |
Why?
|
| Bayes Theorem | 2 | 2021 | 316 | 0.200 |
Why?
|
| Medicare | 3 | 2021 | 463 | 0.200 |
Why?
|
| Polymethacrylic Acids | 1 | 2022 | 5 | 0.200 |
Why?
|
| Bone Diseases | 1 | 2022 | 44 | 0.190 |
Why?
|
| Musculoskeletal Diseases | 1 | 2023 | 59 | 0.190 |
Why?
|
| Phenotype | 3 | 2022 | 4552 | 0.190 |
Why?
|
| Sarcopenia | 1 | 2022 | 56 | 0.190 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2024 | 139 | 0.190 |
Why?
|
| Pattern Recognition, Automated | 2 | 2014 | 49 | 0.190 |
Why?
|
| Patella | 2 | 2019 | 28 | 0.180 |
Why?
|
| Adipose Tissue | 3 | 2022 | 503 | 0.180 |
Why?
|
| Calcinosis | 1 | 2022 | 193 | 0.180 |
Why?
|
| Exercise Tolerance | 2 | 2019 | 86 | 0.180 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2022 | 66 | 0.180 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2021 | 27 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 396 | 0.170 |
Why?
|
| Fibula | 1 | 2020 | 20 | 0.170 |
Why?
|
| Fractures, Bone | 1 | 2022 | 212 | 0.170 |
Why?
|
| Foundations | 1 | 2020 | 22 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2016 | 1243 | 0.160 |
Why?
|
| Swimming | 1 | 2019 | 28 | 0.160 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 3986 | 0.160 |
Why?
|
| Football | 1 | 2020 | 36 | 0.160 |
Why?
|
| Health Status | 3 | 2019 | 412 | 0.160 |
Why?
|
| Reproducibility of Results | 11 | 2018 | 3035 | 0.160 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17433 | 0.160 |
Why?
|
| Gout | 1 | 2022 | 167 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2014 | 817 | 0.160 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 30 | 0.160 |
Why?
|
| Nonprescription Drugs | 1 | 2019 | 54 | 0.160 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 37 | 0.160 |
Why?
|
| Algorithms | 3 | 2019 | 1734 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 67 | 0.150 |
Why?
|
| Veterans Health | 1 | 2021 | 179 | 0.150 |
Why?
|
| Sleep | 2 | 2020 | 370 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 150 | 0.150 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 5467 | 0.150 |
Why?
|
| Running | 1 | 2018 | 34 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 341 | 0.140 |
Why?
|
| Hyperphosphatemia | 1 | 2018 | 18 | 0.140 |
Why?
|
| Sucrose | 1 | 2018 | 43 | 0.140 |
Why?
|
| Genu Varum | 1 | 2017 | 1 | 0.140 |
Why?
|
| Pediatrics | 1 | 2007 | 1210 | 0.140 |
Why?
|
| Ferric Compounds | 1 | 2018 | 41 | 0.140 |
Why?
|
| Inflammation | 2 | 2022 | 1591 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1659 | 0.140 |
Why?
|
| Patellofemoral Joint | 2 | 2014 | 6 | 0.140 |
Why?
|
| Muscle, Skeletal | 4 | 2024 | 1043 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 936 | 0.140 |
Why?
|
| Depression | 4 | 2021 | 1358 | 0.130 |
Why?
|
| Communication | 3 | 2011 | 542 | 0.130 |
Why?
|
| Sex Characteristics | 1 | 2019 | 335 | 0.130 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2016 | 10 | 0.130 |
Why?
|
| Hip Joint | 1 | 2016 | 47 | 0.130 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2016 | 21 | 0.130 |
Why?
|
| Single-Blind Method | 2 | 2017 | 250 | 0.130 |
Why?
|
| Chronic Disease | 3 | 2012 | 1255 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2018 | 276 | 0.120 |
Why?
|
| Orthopedic Procedures | 1 | 2016 | 76 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2017 | 145 | 0.120 |
Why?
|
| Bone Density | 2 | 2018 | 374 | 0.120 |
Why?
|
| Incidental Findings | 1 | 2016 | 129 | 0.120 |
Why?
|
| Machine Learning | 1 | 2019 | 334 | 0.120 |
Why?
|
| Image Enhancement | 3 | 2010 | 171 | 0.120 |
Why?
|
| Atlases as Topic | 1 | 2014 | 17 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 615 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1337 | 0.110 |
Why?
|
| Attitude to Health | 2 | 2007 | 262 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 1492 | 0.110 |
Why?
|
| Models, Statistical | 2 | 2014 | 505 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2011 | 235 | 0.110 |
Why?
|
| Exercise Test | 2 | 2015 | 264 | 0.110 |
Why?
|
| Mobility Limitation | 1 | 2013 | 33 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 319 | 0.100 |
Why?
|
| Treatment Refusal | 2 | 2016 | 80 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2016 | 573 | 0.100 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2023 | 139 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 360 | 0.090 |
Why?
|
| Anemia | 1 | 2016 | 349 | 0.090 |
Why?
|
| Housing for the Elderly | 1 | 2011 | 1 | 0.090 |
Why?
|
| Bone Cysts | 1 | 2011 | 3 | 0.090 |
Why?
|
| Biomarkers | 5 | 2023 | 3430 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2014 | 727 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2013 | 1487 | 0.090 |
Why?
|
| Hypertension | 1 | 2020 | 1396 | 0.090 |
Why?
|
| Muscle Weakness | 1 | 2012 | 94 | 0.090 |
Why?
|
| Pennsylvania | 4 | 2013 | 60 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2012 | 343 | 0.090 |
Why?
|
| Bursitis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 449 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 332 | 0.090 |
Why?
|
| Popliteal Cyst | 1 | 2010 | 3 | 0.090 |
Why?
|
| Acceleration | 1 | 2010 | 30 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 133 | 0.090 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 91 | 0.090 |
Why?
|
| Accelerometry | 3 | 2017 | 64 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2025 | 1153 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 239 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2011 | 93 | 0.090 |
Why?
|
| Bone Malalignment | 1 | 2010 | 4 | 0.080 |
Why?
|
| Low Back Pain | 1 | 2010 | 40 | 0.080 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2011 | 82 | 0.080 |
Why?
|
| Edema | 1 | 2011 | 140 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 847 | 0.080 |
Why?
|
| Risk | 3 | 2023 | 835 | 0.080 |
Why?
|
| Professional Competence | 1 | 2011 | 98 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 914 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 904 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 213 | 0.080 |
Why?
|
| Medicaid | 2 | 2022 | 254 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1868 | 0.080 |
Why?
|
| Thermography | 1 | 2008 | 12 | 0.070 |
Why?
|
| Arthrography | 2 | 2018 | 6 | 0.070 |
Why?
|
| Adiposity | 2 | 2024 | 206 | 0.070 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2018 | 707 | 0.070 |
Why?
|
| Ohio | 2 | 2011 | 87 | 0.070 |
Why?
|
| Databases as Topic | 1 | 2007 | 77 | 0.070 |
Why?
|
| Young Adult | 4 | 2019 | 9883 | 0.070 |
Why?
|
| Age Factors | 3 | 2012 | 2990 | 0.070 |
Why?
|
| Prognosis | 5 | 2016 | 5073 | 0.070 |
Why?
|
| Telephone | 1 | 2007 | 127 | 0.070 |
Why?
|
| Symptom Assessment | 2 | 2018 | 108 | 0.060 |
Why?
|
| Knee Prosthesis | 2 | 2005 | 17 | 0.060 |
Why?
|
| Philadelphia | 2 | 2021 | 27 | 0.060 |
Why?
|
| Emergencies | 1 | 2007 | 185 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2007 | 1488 | 0.060 |
Why?
|
| Adolescent | 6 | 2019 | 20541 | 0.060 |
Why?
|
| Hip | 1 | 2004 | 20 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2936 | 0.060 |
Why?
|
| Tomography, Optical Coherence | 1 | 2010 | 568 | 0.060 |
Why?
|
| United Kingdom | 2 | 2016 | 242 | 0.060 |
Why?
|
| Religion | 1 | 2004 | 51 | 0.060 |
Why?
|
| Gardening | 1 | 2024 | 16 | 0.050 |
Why?
|
| Thigh | 1 | 2024 | 53 | 0.050 |
Why?
|
| Child | 4 | 2019 | 25780 | 0.050 |
Why?
|
| Research Design | 2 | 2018 | 747 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2007 | 519 | 0.050 |
Why?
|
| ROC Curve | 2 | 2017 | 610 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3483 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 271 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2022 | 105 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2002 | 26 | 0.050 |
Why?
|
| Sickness Impact Profile | 1 | 2002 | 39 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2007 | 1090 | 0.050 |
Why?
|
| Uric Acid | 1 | 2022 | 110 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2002 | 40 | 0.050 |
Why?
|
| Social Perception | 1 | 2002 | 59 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2014 | 197 | 0.050 |
Why?
|
| Organ Size | 2 | 2013 | 467 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2005 | 571 | 0.040 |
Why?
|
| Unemployment | 1 | 2021 | 23 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 19 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2022 | 124 | 0.040 |
Why?
|
| Injections, Intra-Articular | 1 | 2020 | 34 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 2166 | 0.040 |
Why?
|
| Sexism | 1 | 2021 | 43 | 0.040 |
Why?
|
| Streptococcaceae | 1 | 2000 | 2 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2004 | 389 | 0.040 |
Why?
|
| Racism | 1 | 2021 | 42 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 255 | 0.040 |
Why?
|
| Observer Variation | 2 | 2011 | 313 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2005 | 678 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2021 | 170 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2007 | 1154 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2000 | 79 | 0.040 |
Why?
|
| Medical Informatics Applications | 1 | 2019 | 24 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2018 | 14 | 0.040 |
Why?
|
| Prescriptions | 1 | 2019 | 43 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 370 | 0.040 |
Why?
|
| Hospitals, Veterans | 2 | 2011 | 364 | 0.040 |
Why?
|
| X-Rays | 1 | 2018 | 30 | 0.040 |
Why?
|
| Phosphorus | 1 | 2018 | 61 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2018 | 205 | 0.030 |
Why?
|
| Poverty | 1 | 2021 | 437 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2022 | 1004 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 284 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 28 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2015 | 1715 | 0.030 |
Why?
|
| North America | 1 | 2017 | 260 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 94 | 0.030 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 132 | 0.030 |
Why?
|
| RNA Polymerase III | 1 | 2016 | 43 | 0.030 |
Why?
|
| Tenosynovitis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Arthritis, Gouty | 1 | 2015 | 6 | 0.030 |
Why?
|
| Arthritis, Psoriatic | 1 | 2015 | 13 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2000 | 307 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 564 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2015 | 59 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2015 | 81 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2018 | 355 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 92 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 453 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 198 | 0.030 |
Why?
|
| Access to Information | 1 | 2014 | 44 | 0.030 |
Why?
|
| Time | 1 | 2014 | 101 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2014 | 105 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 173 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2005 | 3162 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2013 | 8 | 0.030 |
Why?
|
| Chicago | 1 | 2013 | 20 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 149 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1309 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2016 | 466 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2013 | 103 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 389 | 0.020 |
Why?
|
| Torque | 1 | 2012 | 8 | 0.020 |
Why?
|
| Tennessee | 1 | 2012 | 34 | 0.020 |
Why?
|
| HIV Infections | 1 | 2004 | 2072 | 0.020 |
Why?
|
| Spin Labels | 1 | 2011 | 39 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2011 | 60 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 36 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2017 | 803 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 826 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 2010 | 22 | 0.020 |
Why?
|
| Ontario | 1 | 2010 | 91 | 0.020 |
Why?
|
| Office Visits | 1 | 2011 | 78 | 0.020 |
Why?
|
| Orthopedics | 1 | 2011 | 77 | 0.020 |
Why?
|
| Internationality | 1 | 2011 | 138 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 141 | 0.020 |
Why?
|
| Arthroscopy | 1 | 2010 | 45 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 77 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 440 | 0.020 |
Why?
|
| Cysts | 1 | 2010 | 104 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 606 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1044 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 454 | 0.020 |
Why?
|
| Public Health | 1 | 2011 | 287 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 2217 | 0.020 |
Why?
|
| Spirituality | 1 | 2008 | 52 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1624 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8592 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2007 | 130 | 0.020 |
Why?
|
| Anxiety | 1 | 2013 | 991 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 444 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 188 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1535 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2009 | 294 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2005 | 294 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2174 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2004 | 162 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 319 | 0.010 |
Why?
|
| Reoperation | 1 | 2004 | 852 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1596 | 0.010 |
Why?
|
| Bacterial Typing Techniques | 1 | 2000 | 104 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 833 | 0.010 |
Why?
|